In this episode, we discuss two controversial topics in the world of immunizations with Dr. Angelo -- the "high-dose" influenza vaccine and the expanded use of PCV13 (Prevnar-13).

In this episode, we review HIV therapy with Dr. Cottreau with a particular focus on Truvada, Atripla, Complera, Stribild, and Triumeq.

In this episode, we discuss the management of overactive bladder, including: oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), trospium (Sanctura), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq), and onabotulinumtoxinA (Botox).

In this episode, we discuss newly approved agents for diabetes mellitus: Afrezza (inhaled human insulin), SGLT2 inhibitors (Invokana, Farxiga, Jardiance), and long-acting GLP-1 agonists (Bydureon, Tanzeum).

In this episode, we review a wide variety of cancer screening guidelines with a particular focus on the two most controversial screening areas: breast cancer screening with mammography and prostate cancer screening with PSA levels.

In this episode, we have a roundtable discussion regarding ASHP Midyear and the process of pursuing a pharmacy residency program.

In this episode, we discuss the new 2013 ACC/AHA obesity guidelines with a particular focus on three medications for obesity: lorcaserin (Belviq), phentermine/topiramate (Qsymia), and orlistat (Xenical, Alli).

In this episode, we review the National Osteoporosis Foundation's osteoporosis guidelines with a particular focus on two newer agents, denosumab (Prolia) and teriparatide (Forteo).

In this episode, we discuss Bordetella pertussis (whooping cough) with Dr. Michael Fennewald.

In this episode, we discuss our clinical "pet peeves" covering allergy histories, creatinine clearance, surrogate endpoints, "me too" enantiomer drugs, and dose-dependent pharmacology of psychiatric medications.